Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for reducing chemotherapy-induced ototoxicity in pediatric and adult cancer patients. Its flagship product, PEDMARK, is FDA and European approved to prevent hearing loss caused by cisplatin. The company relies on licensing, patent protection, third-party manufacturing, and targeted reimbursement strategies to serve global markets, emphasizing innovation in rare disease therapeutics.
This description was generated via AI from an annual report. Updated about 1 year ago.